Compare Emerson Electric Co. (EMR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Merck & Co., Inc. — how do they compare? Emerson Electric Co. trades at $163.73 (market cap $91.37B), while Merck & Co., Inc. trades at $133.33 (market cap $327.94B). The key difference: Merck & Co., Inc. is far larger — about 3.6× Emerson Electric Co.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.56%). Which is the better fit depends on your goals.
| EMR | MRK | |
|---|---|---|
Market Cap | $91.37B | $327.94B |
Sector | Industrials | Health |
52-Week High | $164.38 | $132.93 |
52-Week Low | $123.30 | $77.60 |
Enterprise Value | $102.44B | $374.70B |
Dividend Yield | 1.36% | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $164.02, up 3.36% with strong technical momentum and bullish analyst sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.71 exceeding expectations. Recent acquisition of Glue Inc. enhances AI capabilities in test & measurement, supporting the raised 2026 outlook. Valuation metrics show P/E of 35.97 and P/S of 4.97, while profitability remains solid with 13.83% net margin.
EMR presents a favorable risk-reward profile with consensus price target of $171.33 offering 4.5% upside potential. Strong organic growth and AI integration drive optimism, though elevated valuation and overbought technical indicators warrant caution. The stock's proximity to 52-week highs suggests near-term consolidation may precede further gains based on execution of growth initiatives.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters with Q3 2026 results pending. Revenue grew to $65.01B in 2025 with net income of $18.25B, though 2026 projections show lower profitability. Recent acquisition activity includes the $6.7B tender offer for Terns Pharmaceuticals to bolster oncology pipeline.
Merck maintains solid fundamentals with 67.6% analyst buy ratings and $140.58 consensus target, offering 7.8% upside. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The stock presents a balanced opportunity with strong institutional support but faces margin compression headwinds in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
